Ryota Matsui, Satoshi Ida, Motonari Ri, Rie Makuuchi, Masaru Hayami, Koshi Kumagai, Manabu Ohashi, Takeshi Sano, Souya Nunobe
BACKGROUND: The relationship between preoperative prealbumin levels and long-term prognoses in patients with gastric cancer after gastrectomy has not been fully investigated. This study clarified the effect of preoperative prealbumin levels on the long-term prognosis of patients with gastric cancer after gastrectomy. METHODS: This retrospective cohort study included consecutive patients who underwent radical gastrectomy for primary pStage I-III gastric cancer and whose preoperative prealbumin levels were measured between May 2006 and March 2017...
February 24, 2024: Gastric Cancer
Jiankun Liu, Tienian Zhu, Ruijing Zhao, Wenjun Ren, Fei Zhao, Jingpu Liu
BACKGROUND: HER2-targeted therapies have improved the outcomes of HER2-positive gastric cancer (GC), yet resistance remains a challenge. We sought to explore the effects of reversible and irreversible HER2 tyrosine kinase inhibitors (TKIs) alone or in combination with the HER2-targeting antibody drug conjugate trastuzumab deruxtecan (T-Dxd). METHODS: The effects of HER2-TKIs on HER2 and downstream signaling were evaluated via Western blotting. Proteasomal inhibitors and co-immunoprecipitation assays were performed to explore the role of proteasomal degradation in HER2 expression modulation, and immunofluorescence assays were employed to explore mechanisms of HER2 internalization...
February 22, 2024: Gastric Cancer
Yuko Kitagawa, Satoru Matsuda, Takuji Gotoda, Ken Kato, Bas Wijnhoven, Florian Lordick, Pradeep Bhandari, Hirofumi Kawakubo, Yasuhiro Kodera, Masanori Terashima, Kei Muro, Hiroya Takeuchi, Paul F Mansfield, Yukinori Kurokawa, Jimmy So, Stefan Paul Mönig, Kohei Shitara, Sun Young Rha, Yelena Janjigian, Daisuke Takahari, Ian Chau, Prateek Sharma, Jiafu Ji, Giovanni de Manzoni, Magnus Nilsson, Paulo Kassab, Wayne L Hofstetter, Elizabeth Catherine Smyth, Sylvie Lorenzen, Yuichiro Doki, Simon Law, Do-Youn Oh, Khek Yu Ho, Tomoyuki Koike, Lin Shen, Richard van Hillegersberg, Hisato Kawakami, Rui-Hua Xu, Zev Wainberg, Naohisa Yahagi, Yeong Yeh Lee, Rajvinder Singh, Min-Hee Ryu, Ryu Ishihara, Zili Xiao, Chika Kusano, Heike Irmgard Grabsch, Hiroki Hara, Ken-Ichi Mukaisho, Tomoki Makino, Mitsuro Kanda, Eisuke Booka, Sho Suzuki, Waku Hatta, Motohiko Kato, Akira Maekawa, Akihito Kawazoe, Shun Yamamoto, Izuma Nakayama, Yukiya Narita, Han-Kwang Yang, Masahiro Yoshida, Takeshi Sano
No abstract text is available yet for this article.
February 22, 2024: Gastric Cancer
Yuki Ito, Mitsuro Kanda, Masahiro Sasahara, Chie Tanaka, Dai Shimizu, Shinichi Umeda, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Goro Nakayama, Yasuhiro Kodera
BACKGROUND: Advanced gastric cancer (GC) has a poor prognosis. This study aimed to identify novel GC-related genes as potential therapeutic targets. METHODS: Killer cell lectin-like receptor G2 (KLRG2) was identified as a candidate gene by transcriptome analysis of metastatic GC tissues. Small interfering RNA-mediated KLRG2 knockdown in human GC cell lines was used to investigate KLRG2 involvement in signaling pathways and functional behaviors in vitro and in vivo...
February 22, 2024: Gastric Cancer
Qing Zhong, Jun-Yu Chen, Zhi-Xin Shang-Guan, Zhi-Yu Liu, Guang-Tan Lin, Dong Wu, Yi-Ming Jiang, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Ju-Li Lin, Jian-Wei Xie, Ping Li, Jun Lu, Chang-Ming Huang, Chao-Hui Zheng
BACKGROUND: Laparoscopy-assisted gastrectomy (LG) is rapidly gaining popularity owing to its minimal invasiveness. Previous studies have found that compared with two-dimensional (2D)-LG, three-dimensional (3D)-LG showed better short-term outcomes. However, the long-term oncological outcomes in patients with locally resectable gastric cancer (GC) remain controversial. METHODS: In this noninferiority, open-label, randomized clinical trial, a total of 438 eligible GC participants were randomly assigned in a 1:1 ratio to either 3D-LG or 2D-LG from January 2015 to April 2016...
February 20, 2024: Gastric Cancer
(no author information available yet)
No abstract text is available yet for this article.
February 14, 2024: Gastric Cancer
Xiulin Zhang, Yang He, Xiaolu Zhang, Bo Fu, Zidai Song, Liang Wang, Rui Fu, Xuancheng Lu, Jin Xing, Jianyi Lv, Meng Guo, Xueyun Huo, Xin Liu, Jing Lu, Xiaoyan Du, Zhongming Ge, Zhenwen Chen, Changlong Li
Helicobacter pylori (H. pylori, Hp) has been designated a class I carcinogen and is closely associated with severe gastric diseases. During colonization in the gastric mucosa, H. pylori develops immune escape by inducing host immune tolerance. The gastric epithelium acts as the first line of defense against H. pylori, with Toll-like receptors (TLRs) in gastric epithelial cells being sensitive to H. pylori components and subsequently activating the innate immune system. However, the mechanism of immune tolerance induced by H...
February 4, 2024: Gastric Cancer
Zev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeño Sanchez, Anita Zahlten-Kümeli, Kate Taylor, Peter C Enzinger
BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7...
February 3, 2024: Gastric Cancer
Anissa Zaafour, Lornella Seeneevassen, Tra Ly Nguyen, Coralie Genevois, Nour Nicolas, Elodie Sifré, Alban Giese, Chloé Porcheron, Jean Descarpentrie, Pierre Dubus, Abdel-Majid Khatib, Christine Varon
BACKGROUND: Gastric cancer (GC), the fourth leading cause of cancer-related death worldwide, with most deaths caused by advanced and metastatic disease, has limited curative options. Here, we revealed the importance of proprotein convertases (PCs) in the malignant and metastatic potential of GC cells through the regulation of the YAP/TAZ/TEAD pathway and epithelial-to-mesenchymal transition (EMT) in cancer stem cells (CSC). METHODS: The general PCs inhibitor, decanoyl-RVKR-chloromethyl-ketone (CMK), was used to repress PCs activity in CSCs of various GC cell lines...
January 27, 2024: Gastric Cancer
Ben Yue, Jianjun Chen, Tianshang Bao, Yuanruohan Zhang, Linxi Yang, Zizhen Zhang, Zheng Wang, Chunchao Zhu
BACKGROUND: Chromosome gains or localized amplifications are frequently observed in human gastric cancer (GC) and are major causes of aberrant oncogene activation. However, the significance of long non-coding RNAs (LncRNAs) in the above process is largely unknown. METHODS: The copy number aberrations (CNAs) data of GC samples were downloaded and analyzed from the TCGA database. qRT-PCR and fluorescence in situ hybridization were used to evaluate the expression of Linc01711 in GC...
January 25, 2024: Gastric Cancer
Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, Tania Capeloa, Cristina Migliore, Claudia Orrù, Gian Luca Baiocchi, Giovanni De Manzoni, Filippo Pietrantonio, Rossella Reddavid, Uberto Fumagalli Romario, Chiara Ambrogio, Simona Corso, Silvia Giordano
BACKGROUND: Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a poor prognosis for patients with advanced disease. Since the oncogenic role of KRAS mutants has been poorly investigated in GC, this study aims to biochemically and biologically characterize different KRAS-mutated models and unravel differences among KRAS mutants in response to therapy. METHODS: Taking advantage of a proprietary, molecularly annotated platform of more than 200 GC PDXs (patient-derived xenografts), we identified KRAS-mutated PDXs, from which primary cell lines were established...
January 23, 2024: Gastric Cancer
Peng Xu, Kanghui Liu, Shansong Huang, Jialun Lv, Zhengyuan Yan, Han Ge, Quan Cheng, Zetian Chen, Peicheng Ji, Yawei Qian, Bowen Li, Hao Xu, Li Yang, Zekuan Xu, Diancai Zhang
BACKGROUND: Peritoneal metastasis (PM), one of the most typical forms of metastasis in advanced gastric cancer (GC), indicates a poor prognosis. Exploring the potential molecular mechanism of PM is urgently necessary, as it has not been well studied. E3 ubiquitin ligase has been widely established to exert a biological function in various cancers, but its mechanism of action in GC with PM remains unknown. METHODS: The effect of MIB1 on PM of GC was confirmed in vitro and in vivo...
January 22, 2024: Gastric Cancer
Masanori Tokunaga, Nozomu Machida, Junki Mizusawa, Seiji Ito, Hiroshi Yabusaki, Motohiro Hirao, Masaya Watanabe, Hiroshi Imamura, Takahiro Kinoshita, Takushi Yasuda, Jun Hihara, Haruhiko Fukuda, Takaki Yoshikawa, Narikazu Boku, Masanori Terashima
BACKGROUND: This randomized phase II study explored the superiority of trastuzumab plus S-1 plus cisplatin (SP) over SP alone as neoadjuvant chemotherapy (NAC) for HER2-positive resectable gastric cancer with extensive lymph node metastasis. METHODS: Eligible patients with HER2-positive gastric or esophagogastric junction cancer and extensive lymph node metastasis were randomized to receive three or four courses of preoperative chemotherapy with SP (arm A) or SP plus trastuzumab (arm B)...
January 19, 2024: Gastric Cancer
Sho Suzuki, Yusuke Monno, Ryo Arai, Masaki Miyaoka, Yosuke Toya, Mitsuru Esaki, Takuya Wada, Waku Hatta, Ayaka Takasu, Shigeaki Nagao, Fumiaki Ishibashi, Yohei Minato, Kenichi Konda, Takahiro Dohmen, Kenji Miki, Masatoshi Okutomi
BACKGROUNDS: Cycle-consistent generative adversarial network (CycleGAN) is a deep neural network model that performs image-to-image translations. We generated virtual indigo carmine (IC) chromoendoscopy images of gastric neoplasms using CycleGAN and compared their diagnostic performance with that of white light endoscopy (WLE). METHODS: WLE and IC images of 176 patients with gastric neoplasms who underwent endoscopic resection were obtained. We used 1,633 images (911 WLE and 722 IC) of 146 cases in the training dataset to develop virtual IC images using CycleGAN...
January 19, 2024: Gastric Cancer
Yoon-Koo Kang, Min-Hee Ryu, Maria Di Bartolomeo, Ian Chau, Harry Yoon, Jong Gwang Kim, Keun-Wook Lee, Sang Chul Oh, Atsuo Takashima, Anna Kryzhanivska, Yee Chao, Ludovic Evesque, Michael Schenker, Arlo McGinn, Yufan Zhao, Jennifer Lee, Lucjan Wyrwicz, Narikazu Boku
BACKGROUND: Rivoceranib is an oral, selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. ANGEL (NCT03042611) was a global, randomized, double-blinded, placebo-controlled, phase 3 study evaluating rivoceranib as 3rd-line or ≥4th-line therapy in patients with advanced/metastatic gastric or gastroesophageal junction (GEJ) cancer. METHODS: Patients had failed ≥2 lines of chemotherapy and were randomized 2:1 to rivoceranib 700 mg once daily or placebo with best supportive care...
March 2024: Gastric Cancer
Matteo Rota, Irene Possenti, Valeria Valsassina, Claudia Santucci, Vincenzo Bagnardi, Giovanni Corrao, Cristina Bosetti, Claudia Specchia, Silvano Gallus, Alessandra Lugo
This study aims at providing an accurate and up-to-date quantification of the dose-response association between cigarette smoking and gastric cancer (GC) risk, overall and by subsite. We conducted a systematic review and meta-analysis of case-control and cohort studies on the association between cigarette smoking and GC risk published up to January 2023. We estimated pooled relative risks (RR) of GC and its subsites according to smoking status, intensity, duration, and time since quitting. Among 271 eligible articles, 205 original studies were included in this meta-analysis...
March 2024: Gastric Cancer
Yukinori Kurokawa, Yuichiro Doki, Ryo Kitabayashi, Takaki Yoshikawa, Takashi Nomura, Kunihiro Tsuji, Masahiro Goto, Haruhiko Cho, Jun Hihara, Naoki Hiki, Souya Nunobe, Junki Mizusawa, Narikazu Boku, Masanori Terashima
BACKGROUND: The prognosis for marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains unfavorable, even after R0 resection. To assess the safety and efficacy of preoperative docetaxel, oxaliplatin, and S-1 (DOS), we conducted a multicenter phase II trial. METHODS: Eligibility criteria included histologically proven HER2-negative gastric adenocarcinoma with bulky nodal (bulky N) involvement around major branched arteries or para-aortic node (PAN) metastases...
March 2024: Gastric Cancer
Bogun Jang, Su-Hyung Lee, Iryna Dovirak, Hyesung Kim, Supriya Srivastava, Ming Teh, Khay-Guan Yeoh, Jimmy B So, Stephen K K Tsao, Christopher J Khor, Tiing Leong Ang, James R Goldenring
BACKGROUND: Mucosal gastric atrophy and intestinal metaplasia (IM) increase the risk for the development of gastric cancer (GC) as they represent a field for development of dysplasia and intestinal-type gastric adenocarcinoma. METHODS: We have investigated the expression of two dysplasia markers, CEACAM5 and TROP2, in human antral IM and gastric tumors to assess their potential as molecular markers. RESULTS: In the normal antral mucosa, weak CEACAM5 and TROP2 expression was only observed in the foveolar epithelium, while inflamed antrum exhibited increased expression of both markers...
January 14, 2024: Gastric Cancer
Chikanori Tsutsumi, Kenoki Ohuchida, Naoki Katayama, Yutaka Yamada, Shoichi Nakamura, Sho Okuda, Yoshiki Otsubo, Chika Iwamoto, Nobuhiro Torata, Kohei Horioka, Koji Shindo, Yusuke Mizuuchi, Naoki Ikenaga, Kohei Nakata, Eishi Nagai, Takashi Morisaki, Yoshinao Oda, Masafumi Nakamura
BACKGROUND: Gastric cancer (GC) is characterized by an immunosuppressive and treatment-resistant tumor immune microenvironment (TIME). Here, we investigated the roles of different immunosuppressive cell types in the development of the GC TIME. METHODS: Single-cell RNA sequencing (scRNA-seq) and multiplex immunostaining of samples from untreated or immune checkpoint inhibitor (ICI)-resistant GC patients were used to examine the correlation between certain immunosuppressive cells and the prognosis of GC patients...
January 13, 2024: Gastric Cancer
Ji-Hyun Kim, Nayoung Kim, Du Hyun Song, Yonghoon Choi, Eun-Bi Jeon, Sihyun Kim, Yu Kyung Jun, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyeon Jeong Oh, Hye Seung Lee, Young Suk Park, Sang-Hoon Ahn, Yun-Suhk Suh, Do Joong Park, Hyung Ho Kim, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Jin Lee, Kyoung Ho Lee, Young Hoon Kim, Soyeon Ahn
BACKGROUND: Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC) has been reported to account for approximately 5-16% of all GCs with good prognosis compared to EBV-negative GC. We evaluated the clinicopathological characteristics of EBVaGC including survival rate in South Korea. METHODS: A total of 4,587 patients with GC who underwent EBV in situ hybridization (EBV-ISH) were prospectively enrolled at the Seoul National University Bundang Hospital from 2003 to 2021...
January 11, 2024: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.